Back to results
US 2019/0169129 A1Published application
Deuterated cftr potentiators
AssigneeVertex Pharmaceuticals (Europe) Limited
InventorAdam J. Morgan
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
Claims21
-19. (canceled)
A process for preparing Compound 106
- or a pharmaceutically acceptable salt thereof, comprising reacting Compound 12
- with Compound 6
- wherein any atom not designated as deuterium is present at its natural isotopic abundance, wherein the percentage of isotopic enrichment for each designated deuterium is at least 90%, and
- optionally treating Compound 106 with a base to produce a pharmaceutically acceptable salt of Compound 106.
1 more element
Dependencies are inferred from the claim text.